## **Core Concept**
The question tests the understanding of managing side effects associated with certain chemotherapeutic agents, specifically those that require urinary alkalinization to prevent or mitigate adverse effects.

## **Why the Correct Answer is Right**
The correct answer, Methotrexate, is a chemotherapeutic agent for which urinary alkalinization is recommended. Methotrexate is excreted primarily by the kidneys, and its solubility in urine decreases with acidic pH. At low pH, methotrexate and its metabolites can precipitate in the renal tubules, leading to acute kidney injury. Alkalinizing the urine to a pH of 7 or higher increases the solubility of methotrexate and its metabolites, thereby reducing the risk of renal precipitation and injury.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because while certain drugs may require careful monitoring of renal function or have specific handling procedures, they are not primarily associated with the need for urinary alkalinization as a standard management strategy.
- **Option B:** Similarly, this option does not directly relate to the necessity of urinary alkalinization as part of its standard administration protocol.
- **Option D:** This option is also incorrect as it does not have a well-established requirement for urinary alkalinization during its administration.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that for patients receiving methotrexate, especially in high doses, maintaining a high urine pH (≥7) is crucial to prevent nephrotoxicity. This is typically achieved by administering bicarbonate and ensuring adequate hydration.

## **Correct Answer:** B. Methotrexate